B-cell maturation antigen CAR-T cell therapy - Pregen ShenZhen Biotechnology

Drug Profile

B-cell maturation antigen CAR-T cell therapy - Pregen ShenZhen Biotechnology

Alternative Names: BCMA CAR-T cell therapy

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pregene ShenZhen Biotechnology
  • Developer Henan Cancer Hospital; Pregene ShenZhen Biotechnology
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 01 Oct 2017 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in China (Infusion) (NCT03322735)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top